Von Willebrand Factor Human

drug
On this page

Also known as Human von willebrand factorVon willebrand factorVon willebrand factor (human)humanVon willebrand's factor

Summary

Von Willebrand Factor Human (CHEMBL4298126) is an approved unknown (ATC B02BD10); indicated across 6 conditions including von willebrand disease (hereditary or acquired) and hemophilia a.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Unknown
  • ATC class: B02BD10
  • Indications: 6 conditions
  • Clinical trials: 4

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL4298126
NameVon Willebrand Factor Human
TypeUnknown
Max phase4
ATCB02BD10

Also known as: Human von willebrand factor, Von willebrand factor, Von willebrand factor (human), Von willebrand factor human, human, Von willebrand’s factor, VON WILLEBRAND FACTOR HUMAN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

IndicationPhaseMONDOEFO
von Willebrand disease (hereditary or acquired)4MONDO:0024574Orphanet:903
hemophilia A4MONDO:0010602MONDO:0010602

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)PhaseMONDOEFO
hemorrhagic disease1MONDO:0002243MONDO:0002243

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

PhaseTrials
Not specified2
PHASE21
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03613584PHASE2UNKNOWNVon Willebrand Factor Concentrate During ECMO Support
NCT00004667PHASE1COMPLETEDPhase I Study of Human Von Willebrand Factor for Von Willebrand’s Disease
NCT02460458Not specifiedCOMPLETEDType 3 Von Willebrand International Registries Inhibitor Prospective Study
NCT05008458Not specifiedUNKNOWNValue of Von Willebrand Factor and Copeptin Assay in Children With Febrile Seizures at Sohag University Hospital

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).